L.I. Vishniakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L.I. Vishniakova has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Musa Rakhimovich Khaitov
National Research Center Institute of Immunology FMBA of Russia Moscow Russian Federation
9 shared publications - Igor P. Shilovskiy
National Research Center Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russia
8 shared publications - Dmitry Anatolievich Kudlay
Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia
7 shared publications - E. D. Timotievich
National Research Center – Institute of Immunology of the Federal Medical-Biological Agency, Moscow
7 shared publications - Kirill V. Yumashev
Allergy and Immunology Research Centre, FMBA of Russia, Moscow
7 shared publications - Aleksandr A. Nikolskii
Allergy and Immunology Research Centre, FMBA of Russia, Moscow
6 shared publications
Latest Publications
- 3 May 2023
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 111 (9) , 1614-1628
Transfection efficacy and drug release depends upon the PEG derivative in cationic lipoplexes: Evaluation in 3D in vitro model and in vivo
The goal of the study was to estimate transfection efficacy and drug release in function of the PEG derivative in cationic liposomes and lipoplexes in both 2D and 3D in vitro models as well as in a mouse model (in vivo). For this purpose, cationic PEGylated nanocarriers based on OrnOrnGlu(C16H33)2 lipopeptides were fabricated and characterized. The nanocarriers were loaded with DNA plasmid pGL3 or with siRNA targeting 5′‐UTR region of Hepatitis C virus, and their transfection efficacies were studied by luciferase test or by PCR technique, respectively. The pGL3‐lipoplexes containing PEG derivative b (6 mol % PEG) were selected as the most promising nanocarriers for further in vivo study. In vitro cytotoxicity assay of the pGL3‐lipoplexes with the PEG derivative b showed 2‐ and 1.5‐fold enhancements of IC50 levels for HEK293T and HepG2 cells, respectively. Accumulation of the liposomes in the cells was studied by confocal microscopy using both 2D (monolayer culture) and 3D (multicellular spheroids) in vitro models. The PEGylated liposomes were found to penetrate cells more slowly than unmodified ones (without PEG). Thus, maximum liposomes in the HEK293T cells was observed after 1 and 3 h in the case of 2D and 3D in vitro models, respectively. Biodistribution study in mice showed that the PEGylated lipoplexes containing the PEG derivative b were eliminated from the bloodstream more slowly, namely with the doubled half‐life time, than unmodified ones. Thus, the enhanced transfection efficacy and prolonged drug release of the PEGylated lipoplexes containing the optimal PEG derivative was demonstrated. This approach could be promising for development of novel siRNA‐based drugs.
- 3 May 2023
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 111 (9) , 1614-1628
Transfection efficacy and drug release depends upon the PEG derivative in cationic lipoplexes: Evaluation in 3D in vitro model and in vivo
The goal of the study was to estimate transfection efficacy and drug release in function of the PEG derivative in cationic liposomes and lipoplexes in both 2D and 3D in vitro models as well as in a mouse model (in vivo). For this purpose, cationic PEGylated nanocarriers based on OrnOrnGlu(C16H33)2 lipopeptides were fabricated and characterized. The nanocarriers were loaded with DNA plasmid pGL3 or with siRNA targeting 5′‐UTR region of Hepatitis C virus, and their transfection efficacies were studied by luciferase test or by PCR technique, respectively. The pGL3‐lipoplexes containing PEG derivative b (6 mol % PEG) were selected as the most promising nanocarriers for further in vivo study. In vitro cytotoxicity assay of the pGL3‐lipoplexes with the PEG derivative b showed 2‐ and 1.5‐fold enhancements of IC50 levels for HEK293T and HepG2 cells, respectively. Accumulation of the liposomes in the cells was studied by confocal microscopy using both 2D (monolayer culture) and 3D (multicellular spheroids) in vitro models. The PEGylated liposomes were found to penetrate cells more slowly than unmodified ones (without PEG). Thus, maximum liposomes in the HEK293T cells was observed after 1 and 3 h in the case of 2D and 3D in vitro models, respectively. Biodistribution study in mice showed that the PEGylated lipoplexes containing the PEG derivative b were eliminated from the bloodstream more slowly, namely with the doubled half‐life time, than unmodified ones. Thus, the enhanced transfection efficacy and prolonged drug release of the PEGylated lipoplexes containing the optimal PEG derivative was demonstrated. This approach could be promising for development of novel siRNA‐based drugs.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Synthetic siRNA molecules suppress Il4 and Il13 gene expression and reduce allergic inflammation and remodeling of upper airways in mouse model
Синтетические молекулы миРНК подавляют экспрессию генов Il4 и Il13 и уменьшают аллергическое воспаление и ремоделирование верхних дыхательных путей в
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Open AccessSynthetic siRNA molecules suppress Il4 and Il13 gene expression and reduce allergic inflammation and remodeling of upper airways in mouse model
Синтетические молекулы миРНК подавляют экспрессию генов Il4 и Il13 и уменьшают аллергическое воспаление и ремоделирование верхних дыхательных путей в
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (4)
Additive effect of synthetic small interfering RNAs targeted to respiratory syncytial virus
Аддитивный эффект синтетических малых интерферирующих РНК в отношении респираторно-синцитиального вируса
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (4)
Open AccessAdditive effect of synthetic small interfering RNAs targeted to respiratory syncytial virus
Аддитивный эффект синтетических малых интерферирующих РНК в отношении респираторно-синцитиального вируса
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
MIR 19® – world first specific antiviral drug for COVID-19 treatment: development and preclinical studies
МИР 19 - первый в мире специфический противовирусный препарат для лечения COVID-19: разработка и доклинические исследования
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
Open AccessMIR 19® – world first specific antiviral drug for COVID-19 treatment: development and preclinical studies
МИР 19 - первый в мире специфический противовирусный препарат для лечения COVID-19: разработка и доклинические исследования
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (2)
A synthetic peptide mimicking the antigenic site of F protein suppresses of respiratory syncytial virus infection in vitro
Синтетический пептид, имитирующий антигенный сайт белка F, подавляет инфекцию респираторно-синцитиального вируса в экспериментах in vitro
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (2)
A synthetic peptide mimicking the antigenic site of F protein suppresses of respiratory syncytial virus infection in vitro
Синтетический пептид, имитирующий антигенный сайт белка F, подавляет инфекцию респираторно-синцитиального вируса в экспериментах in vitro
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (6)
A mouse model of allergic rhinitis mimicking human pathology
Модель аллергического ринита у мышей, имитирующая основные проявления патологии человека
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (6)
A mouse model of allergic rhinitis mimicking human pathology
Модель аллергического ринита у мышей, имитирующая основные проявления патологии человека
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (4)
Mouse model of respiratory syncytial virus infection mimicking acute human pathology
Модель респираторно-синцитиальной вирусной инфекции у мышей, имитирующая основные проявления патологии человека
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (4)
Mouse model of respiratory syncytial virus infection mimicking acute human pathology
Модель респираторно-синцитиальной вирусной инфекции у мышей, имитирующая основные проявления патологии человека
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (3)
Supercationic peptide dendrimers as vectors for nucleic acids delivery to mammalian cells
Суперкатионные пептидные дендримеры как векторы для доставки нуклеиновых кислот в клетки млекопитающих
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (3)
Supercationic peptide dendrimers as vectors for nucleic acids delivery to mammalian cells
Суперкатионные пептидные дендримеры как векторы для доставки нуклеиновых кислот в клетки млекопитающих
- 1 January 2021
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 42 (6)
Effect of local suppression of Stat3 gene expression in a mouse model of pulmonary neutrophilic inflammation
Влияние локального подавления экспрессии гена Stat3 на нейтрофильное воспаление легких в экспериментальной модели на мышах
- 1 January 2021
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 42 (6)
Effect of local suppression of Stat3 gene expression in a mouse model of pulmonary neutrophilic inflammation
Влияние локального подавления экспрессии гена Stat3 на нейтрофильное воспаление легких в экспериментальной модели на мышах